secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001213900-25-010747
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma receives permanent J-code J9161 for LYMPHIR, effective April 1, 2025
--------------------------------------------------------------------------------

- CMS assigned permanent HCPCS J-code J9161 to LYMPHIR (denileukin diftitox-cxdl) for CTCL.
- J-code effective April 1, 2025, streamlines billing and reimbursement for providers.
- LYMPHIR approved by FDA for relapsed/refractory Stage I-III CTCL after prior systemic therapy.
- CEO Leonard Mazur says J-code is critical for patient access and coverage by commercial & government insurers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025010747/0001213900-25-010747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025010747/ea0230159-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-010747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer